ANTIBIOTIC DEVELOPMENT IN PHARMA IS DEAD – FOR NOW

This is a somewhat nostalgic retro blog.  I was leafing through a book by Vince Andriole called ‘The Quinolones’.[1]  First released in 1988, its third edition is from 2000.  It provided in-depth coverage of quinolone chemistry, PK, microbiology, efficacy and safety.  It was a great review of the large and Continue reading ANTIBIOTIC DEVELOPMENT IN PHARMA IS DEAD – FOR NOW

The Tiragolumab Saga & Tifacogin Flash-Backs

A recent Nature Review Drug Discovery article caught our attention, a review of TIGIT as an IO target and the failed Phase 3 study of tiragolumab which is the TIGIT inhibitor from Roche.[1]  The science writer interviewed a group of insiders that had a lead role in the development of Continue reading The Tiragolumab Saga & Tifacogin Flash-Backs

Obeldesivir Fails in Yet Another Study

There are studies that are bound to succeed, and those that are likely to fail.  A failed trial is nothing to be proud of – and in this case, it was a gamble against overwhelming odds.  We feel the Gilead marketing department was pushing their luck big time with this Continue reading Obeldesivir Fails in Yet Another Study